Archive for the ‘Gene Therapy Research’ Category

Public release date: 16-Jan-2013 [ | E-mail | Share ]

Contact: Jean-Franois Hupp jean-francois.huppe@dc.ulaval.ca 418-656-7785 Universit Laval

This press release is available in French.

Quebec City, January 16, 2013Genetics plays a major role in peer rejection and victimization in early elementary school, according to a study recently published on the website of the journal Child Development by a team directed by Dr. Michel Boivin, a research professor at Universit Laval's School of Psychology.

To come to this conclusion, Boivin and his team tested over 800 twins at three time points: when they were in kindergarten, Grade 1, and Grade 4. This sample consisted of 41% monozygotic twins"true" twins who share 100% of their genesand 59% "false," or fraternal twins who share an average of 50% of their genes. Each subject, their classmates, and their teacher were asked questions relating to peer rejection and victimization.

The research revealed that pairs of twins presented significant similarities with respect to relationship problems. Their analyses determined that these similarities were over 73% attributable to genetic factors. "Certain genetically transmissible traits that underlie physical appearance or behaviorparticularly aggressive, impulsive, and hyperactive behaviorsincrease the risk of rejection or victimization," asserts Michel Boivin, holder of the Canada Research Chair in Child Development.

Researchers also noted that relationship problems persisted between kindergarten and Grade 4, largely due to genetic factors.

"The good news is that it is possible, in kindergarten if not earlier, to identify children who might have trouble relating to their peers and quickly intervene," stresses Boivin. "We have to keep the personal characteristics that make them less popular with other kids from creating a vicious circle of rejection and victimization."

Between 5 and 10% of children experience chronic rejection or victimization in elementary school. These relationship difficulties can lead to academic problems, health issues, and a series of mental health complications like depression, anxiety, and suicidal ideation. "That's why it's so important to know when and how these problems appear and develop," concludes Dr. Boivin.

###

Originally posted here:
Genetics plays major role in victimization in elementary school

SALT LAKE CITY, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) today announced that it will issue financial results for the second fiscal quarter 2013 following the close of market on Tuesday, February 5, 2013.

The Company will also host a conference call on Tuesday, February 5, 2013 at 4:30 P.M. Eastern to review the financial results. Participating on the call will be: Peter Meldrum, President and Chief Executive Officer, Mark Capone, President of Myriad Genetic Laboratories, Inc. and Jim Evans, Chief Financial Officer.

To listen to the call, interested parties within the U.S. may dial 800-732-6870, or +1 212-231-2900 for international callers. All callers will be asked to reference reservation number 21645936.

The conference call will also be available through a live webcast at http://www.myriad.com.

A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the U.S. or +1 402-977-9140 for international callers, and entering reservation number 21645936.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Follow this link:
Myriad Genetics to Announce Second Fiscal Quarter 2013 Results on Tuesday, February 5, 2013

The Sea Slug That Eats The Sun: Sidney Pierce at TEDx TampaBay (The Future of Stories)
Dr. Sidney Pierce is currently a professor at the University of South Florida #39;s Department of Integrative Biology. His current research involves photosynthetic animals, especially the molecular biology behind the intracellular symbiosis between the digestive cells of a sea slug (Elysia chlorotica) and algal (Vaucheria litorea) chloroplasts, with applications in medicine mdash;gene therapy. Dr. Pierce #39;s work has been featured on radio, TV, newspapers, magazines, and even Weekly Reader, internationally as well as domestically. In fact, his research was recently featured in a French documentary, "The Power of Plants" on the France 5 network in France.

By: TEDxTalks

Read more:
The Sea Slug That Eats The Sun: Sidney Pierce at TEDx TampaBay (The Future of Stories) - Video

Washington, January 16 (ANI): In a preliminary study in a canine model of Duchenne muscular dystrophy (DMD), researchers have shown a giant leap using gene therapy to treat muscular dystrophy.

Muscular dystrophy occurs when damaged muscle tissue is replaced with fibrous, bony or fatty tissue and loses function. Duchenne muscular dystrophy is the most common type of muscular dystrophy predominantly affecting boys.

Patients with DMD have a gene mutation that disrupts the production of dystrophin, a protein essential for muscle cell survival and function. Absence of dystrophin starts a chain reaction that eventually leads to muscle cell degeneration and death.

For years, scientists have been working to find the key to restoring dystrophin, but they have faced many challenges.

One of the largest hurdles in DMD gene therapy is the large size of the gene. Dystrophin is the largest gene in the human genome, containing approximately 4,000 amino acids.

To fit the dystrophin gene into a vehicle that could deliver the gene to the appropriate site in the body, one has to delete 70 percent of the gene. The highly abbreviated gene is known as the "micro-dystrophin" gene.

Previous studies suggest that micro-dystrophin can effectively stop muscle disease in mice that are missing dystrophin. However, mice that are missing dystrophin show minimal DMD symptoms, and results from mice often do not predict what will happen in humans.

In contrast to mice, loss of dystrophin results in severe muscular dystrophy in dogs. If micro-dystrophin can work in dystrophic dogs, it will likely work in human patients. Unfortunately, when micro-dystrophin was tested in dogs in previous studies, it was not successful.

To overcome these hurdles, a team led by Dongsheng Duan, the Margaret Proctor Mulligan Professor in Medical Research at the University of Missouri School of Medicine, engineered a new micro-dystrophin gene that carries an important functional region missing in previously tested micro-dystrophins.

"We placed the new microgene into a virus and then injected the virus into dystrophic dogs' muscles," Duan said.

Here is the original post:
Experts take quantum leap in gene therapy to treat muscular dystrophy

SILVER SPRING, Md., Jan. 15, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing natural products and cell and gene therapy solutions for the treatment of human diseases, announced today its subsidiary, KnockOut Technologies, Ltd., has filed a patent in Thailand for all-natural product formulations and their potential use in preventing and treating infections caused by influenza viruses.

The initial patent application was filed in January of 2008 and after a lengthy review process it was resubmitted to patent officials in Thailand by our counsel this week. The all-natural formulations described in the patent have the potential to impact upon outbreaks of influenza virus infections. Thailand was chosen for submission of this patent in 2008 as a result of endemic influenza in that region.

"Seasonal" influenza (flu) is an acute viral infection that can affect all age groups, but children under two years of age, adults over 65, and those with weakened immune systems or with other serious illnesses such as diabetes, chronic heart, lung, and liver diseases, are at the highest risk. According to the World Health Organization (WHO), annual epidemics of seasonal flu result in about 3-5 million cases of severe illness and about 250,000-500,000 deaths worldwide.

The natural patent formulations contain a mixture of orange oils. In standard laboratory tests used to determine antiviral activity, our formulations containing these ingredients were shown to be effective in killing these flu viruses.

We believe acceptance of this patent represents an important step in the development of all-natural anti-viral formulations that will ultimately lead to approval by regulatory authorities for the sale of one or more products. Nuvilex has been planning to continue to expand its present work with groups in Thailand to aid in combating viruses particularly in Southeast Asia. The Company hopes to receive approval of the patent within 90-180 days.

About Nuvilex

Nuvilex, Inc. (NVLX) has been a provider of all-natural products for many years and has expanded its company to become an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. In the biotechnology area of Nuvilex, our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

Excerpt from:
Nuvilex's Subsidiary Files International Patent for All-Natural Flu Virus Treatment

Associate Professor David Harrich, who works in the QIMR's Molecular Virology Laboratory on HIV. PIC: Liam Kidston. Source: The Courier-Mail

A QUEENSLAND researcher has developed a gene therapy for HIV which has the potential to stop the virus from turning deadly.

Queensland Institute of Medical Research scientist David Harrich will begin animal trials this year, with experiments in humans are still five years away.

Associate Professor Harrich has manipulated an HIV protein involved in gene expression, known as Tat, and turned it into a weapon against the virus.

Using human immune system cells, known as T cells, in the laboratory, he's shown the mutant protein prevents HIV replication.

At the same time, Prof Harrich said the modified protein, dubbed Nullbasic, did not appear to adversely affect the human cells.

"So far we haven't found that Nullbasic causes toxicity in the cells we've tested," he said.

"I'm excited. Every test I've done with this agent has succeeded. It makes me optimistic it will work in humans. At the same time, I'm a sceptical scientist and I'm going to require proof it can jump every hurdle." QIMR researchers will soon begin testing the protein in mice.

"Before you can trial it on humans, it's going to have to go through rigorous testing in animals for safety," Professor Harrich said.

In order for human cells to make the HIV-inhibitory protein in the laboratory, he had to insert a new gene - a process known as gene therapy.

Read the original here:
Researcher has HIV control in sight

A gene has been uncovered that may help to create born leaders.

The leadership gene, known as rs4950, is an inherited DNA sequence associated with people taking charge.

Scientists accept that leadership skills are also learned. But the gene may provide the vital push needed to make someone into a manager rather than a minion.

Researchers found the gene after analysing DNA samples from around 4,000 individuals and matching them to information about jobs and relationships. Workplace supervisory roles were used as a measurement of leadership behaviour.

The study showed that a quarter of the observed variation in leadership traits between individuals could be explained by genetics.

Lead scientist Dr Jan-Emmanuel De Neve, from University College London, said: "We have identified a genotype, called rs4950, which appears to be associated with the passing of leadership ability down through generations.

"The conventional wisdom - that leadership is a skill - remains largely true, but we show it is also, in part, a genetic trait."

The findings appear online in the journal Leadership Quarterly.

Some of the greatest leaders in recent history include Martin Luther King, Gandhi, Nelson Mandela and Sir Winston Churchill. The new research suggests at least the possibility that some of these historic figures were blessed with the leadership gene.

Despite the importance of the gene, acquiring a leadership position still mostly depends on developing the necessary skills, said the researchers.

Excerpt from:
Scientists find leadership gene

Gene Robinson, the first openly gay bishop in the Episcopal Church, has retired. He'll start working with the Center for American Progress, a progressive research and policy organization, on issues of faith and gay rights.

Gene Robinson, the first openly gay bishop in the Episcopal Church, has retired. He'll start working with the Center for American Progress, a progressive research and policy organization, on issues of faith and gay rights.

For many years, it didn't occur to Bishop Gene Robinson the first openly gay bishop in the Episcopal Church that he might retire before age 72, the mandatory retirement age for Episcopal bishops. But then, in 2010, Mary Glasspool, who is also openly gay, was elected bishop suffragan in the Diocese of Los Angeles and, for the first time, Robinson reconsidered his retirement plans.

"I thought, you know, I don't have to keep doing this," he tells Fresh Air's Terry Gross. "There is an openly gay voice in the House of Bishops, and is there something else that I would really like to do and perhaps that God is calling me to do? And that answer came back 'yes.' And so ... I announced that I would retire at the end of 2012."

Robinson, 65, retired from his position as bishop of the Diocese of New Hampshire on Jan. 5. He and his husband, Mark, will be leaving the state where Robinson has lived and worked since 1975 for Washington, D.C. There, Robinson will be working with the Center for American Progress, a progressive research and policy organization, on issues of faith and gay rights.

"I've long been really intrigued with what is the ... proper role of faith and religion in public life," he says. "How do we address the issues that face us as a nation, and what might the church, the synagogue, the mosque have to say to those issues, and what's the proper way of making that input into this larger discussion?"

Robinson, whose most recent book, God Believes in Love: Straight Talk About Gay Marriage, was published in September, is an outspoken advocate of LGBT rights, the fight he likens to the civil rights movement.

"Gay is not something we do," he says. "It's something we are. I'm not just gay when I'm making love to my husband. I'm gay all the time. I'm gay right this minute talking to you, and it ... affects how I relate to the world, how I relate to people."

On whether the death threats he and his husband have received contributed to his decision to retire early

"That's really not the reason, although I would be lying if I said that wasn't an extra burden that my husband, Mark, and I have endured during this time. The death threats were plentiful, almost daily for a couple of years. And then more recently ... I prayed the invocation at the opening inaugural event at President Obama's inauguration in 2009, and it was about two weeks later I got a call from the Vermont State Police who had almost accidentally arrested a guy who had been driving through this small Vermont town and was in such a rage that he shot the windows out of an empty parked police cruiser. And when they caught up to him, he had in his passenger's seat, right next to him, he had MapQuest maps right to our house. He had pictures of me and Mark, and he had scrawled across them, 'Save the church. Kill the bishop.' And he had a sawed-off shotgun and tons of ammunition."

Read the original:
Retired Bishop Gene Robinson On Being Gay And Loving God

Public release date: 14-Jan-2013 [ | E-mail | Share ]

Contact: Jennifer Brown jennifer-l-brown@uiowa.edu 319-356-7124 University of Iowa Health Care

Scientists from the University of Iowa and Brigham Young University (BYU) have identified a gene that may be a target for overcoming drug resistance in cancer. The finding could not only improve prognostic and diagnostic tools for evaluating cancer and monitoring patients' response to treatment but also could lead to new therapies directed at eradicating drug-resistant cancer cells.

Drug resistance is a common problem in many metastatic cancers. It leads to failure of chemotherapy treatments and is associated with poor patient outcomes, including rapid relapse and death.

The research team, including Fenghuang (Frank) Zhan, M.D., Ph.D., and Guido Tricot, M.D., Ph.D., from the UI, and David Bearss, Ph.D., from BYU, initially focused on identifying genes linked to the development of drug resistance in multiple myeloma, a bone marrow cancer that affects more than 20,000 Americans and causes almost 11,000 deaths annually.

Working with serial biopsied cells from 19 myeloma patients, the researchers analyzed genetic changes in the cells that occurred over the course of treatment with very intensive chemotherapy drugs. This approach identified a gene called NEK2 that is strongly associated with increased drug-resistance, faster cancer growth, and poorer survival for patients. The study was published Jan. 14 in the journal Cancer Cell.

Having established the relationship between high expression of the NEK2 gene and poor patient outcome in myeloma, the team then examined the relationship in other common cancers -- including breast, lung, and bladder cancer -- by analyzing gene expression profiles from 2,500 patients' cells with eight different cancers in Zhan's lab.

"In all cases, an increase in the NEK2 gene was associated with rapid death of the patient," says Tricot, who is director of Holden Comprehensive Cancer Center's Bone Marrow Transplant and Myeloma Program at UI Hospitals and Clinics. "So this finding was not unique to myeloma; this is basically seen in every single cancer we looked at."

Taking the findings back to the lab, the team then examined the effect on cancer cells of either enhancing or blocking the expression of the NEK2 gene.

"Our studies show that over-expression of NEK2 in cancer cells significantly enhances the activity of drug efflux proteins to pump chemotherapy drugs out of cells, resulting in drug resistance. Furthermore, silencing NEK2 in cancer cells potently decreased drug resistance, induced cell-cycle arrest, cell death, and inhibited cancer cell growth in vitro and in vivo," says Zhan, UI professor of internal medicine.

See the original post:
Team finds gene that promotes drug resistance in cancer

Public release date: 14-Jan-2013 [ | E-mail | Share ]

Contact: John Ascenzi ascenzi@email.chop.edu 267-426-6055 Children's Hospital of Philadelphia

Genetics researchers have identified 25 additional copy number variations (CNVs)missing or duplicated stretches of DNAthat occur in some patients with autism. These CNVs, say the researchers, are "high impact": although individually rare, each has a strong effect in raising an individual's risk for autism.

"Many of these gene variants may serve as valuable predictive markers," said the study's corresponding author, Hakon Hakonarson, M.D., Ph.D., director of the Center for Applied Genomics at The Children's Hospital of Philadelphia. "If so, they may become part of a clinical test that will help evaluate whether a child has an autism spectrum disorder."

Hakonarson collaborated with scientists from the University of Utah and the biotechnology company Lineagen, Inc., in the study, published today in the journal PLOS ONE.

The current study builds on and extends previous gene research by Hakonarson and other scientists on autism spectrum disorders (ASDs), a group of childhood neurodevelopmental disorders that cause impairments in verbal communication, social interaction and behavior. Estimated by the CDC to affect as many as one in 88 U.S. children, ASDs are known from family studies to be strongly influenced by genetics.

In the current study, the researchers first analyzed DNA from 55 individuals from Utah families with multiple members diagnosed with ASDs. Study co-author Mark Leppert, Ph.D., of the University of Utah, had collected the data from these high-risk families. The team identified 153 CNVs as potentially specific to autism.

To investigate these CNVs in a broader ASD population, the study team custom-designed a DNA array with probes for those 153 CNVs, as well as for another 185 CNVs previously reported to be associated with autism. They then analyzed the actual prevalence of all the CNVs in a larger sample set of 3,000 ASD cases and 6,000 control subjects previously gathered in studies by The Children's Hospital of Philadelphia.

The researchers found that 15 of the CNVs found in the family studies, in addition to nine other CNVs found by their custom array, all had odds ratios greater than 2.0, meaning that subjects with those variants had at least two-fold increased risk of having an ASD, compared to controls. Another 31 CNVs previously reported to be associated with autism also had odds ratios above 2.0.

These findings, said Hakonarson, could be incorporated into clinical tests for evaluating children for ASDs. "These high-impact variants could be most useful in advising parents who already have one child with an ASD," said Hakonarson. "If a second child has delays in reaching developmental milestones, testing for these CNVs could help predict whether that child is also likely to develop an ASD." He added that the newly identified variants would need to be added to the existing commercially available diagnostic array in current use.

See the original post here:
New autism-related gene variants discovered

Jan. 14, 2013 Scientists from the University of Iowa and Brigham Young University (BYU) have identified a gene that may be a target for overcoming drug resistance in cancer. The finding could not only improve prognostic and diagnostic tools for evaluating cancer and monitoring patients' response to treatment but also could lead to new therapies directed at eradicating drug-resistant cancer cells.

Drug resistance is a common problem in many metastatic cancers. It leads to failure of chemotherapy treatments and is associated with poor patient outcomes, including rapid relapse and death.

The research team, including Fenghuang (Frank) Zhan, M.D., Ph.D., and Guido Tricot, M.D., Ph.D., from the UI, and David Bearss, Ph.D., from BYU, initially focused on identifying genes linked to the development of drug resistance in multiple myeloma, a bone marrow cancer that affects more than 20,000 Americans and causes almost 11,000 deaths annually.

Working with serial biopsied cells from 19 myeloma patients, the researchers analyzed genetic changes in the cells that occurred over the course of treatment with very intensive chemotherapy drugs. This approach identified a gene called NEK2 that is strongly associated with increased drug-resistance, faster cancer growth, and poorer survival for patients. The study was published Jan. 14 in the journal Cancer Cell.

Having established the relationship between high expression of the NEK2 gene and poor patient outcome in myeloma, the team then examined the relationship in other common cancers -- including breast, lung, and bladder cancer -- by analyzing gene expression profiles from 2,500 patients' cells with eight different cancers in Zhan's lab.

"In all cases, an increase in the NEK2 gene was associated with rapid death of the patient," says Tricot, who is director of Holden Comprehensive Cancer Center's Bone Marrow Transplant and Myeloma Program at UI Hospitals and Clinics. "So this finding was not unique to myeloma; this is basically seen in every single cancer we looked at."

Taking the findings back to the lab, the team then examined the effect on cancer cells of either enhancing or blocking the expression of the NEK2 gene.

"Our studies show that over-expression of NEK2 in cancer cells significantly enhances the activity of drug efflux proteins to pump chemotherapy drugs out of cells, resulting in drug resistance. Furthermore, silencing NEK2 in cancer cells potently decreased drug resistance, induced cell-cycle arrest, cell death, and inhibited cancer cell growth in vitro and in vivo," says Zhan, UI professor of internal medicine.

The research team is now developing compounds to inhibit NEK2 by collaborating with David Bearss, Ph.D., associate professor of physiology and developmental biology at BYU, in the hope that these compounds may overcome drug resistance in cancer cells.

"We were able to show that if we inhibit NEK2, then we can actually restore sensitivity to drugs that we use right now," Bearss says.

Read the original:
Gene promotes drug resistance in cancer

"Road to Executive Leadership" - GHC India 2012
Moderator: Nivedita Aggarwal, CA Technologies Panelists: Soumitra Agarwal, EMA Partners International; Aparna Gupta, FirstRain; Shalini Kapoor, Executive Architect-IBM SWG Labs; Dr. Kiranmai Dutt Pendyala, AMD Reports suggest that over the years the number of executive leadership positions available have increased, but the number of women holding these positions have decreased. Though there is a decent representation of women in mid-to senior-levels, women continue to remain significantly under-represented on boards due to lack of significant strategies in place. This panel discussion will help uncover the golden nuggets of wisdom, and strategies and stories about how some women were able to rise on top of their chosen profession despite the hurdles that came along. The panelists of this session have achieved leadership roles and have reached there with a reputation of delivering key results. They are comfortable embracing power and are credible and strategic. The panelists will also share their views on what companies look for while hiring for executive positions. Nivedita Aggarwal, Director, Technical Information, CA Technologies Nivedita is a Director at CA Technologies (India) with a team of 70+ talented team members working out of different locations-- Hyderabad, Bangalore, and Australia. With more than 12 years of experience in the IT industry, including 7+ years in various management roles, her responsibilities varied from training, user documentation, people ...

By: abiwt

Read more here:
"Road to Executive Leadership" - GHC India 2012 - Video

Persuasive Speech: Genetic Engineering
Here is my speech on Genetic Engineering: the way of manipulating genes to make our bodies better.

By: Monica Mulder

Go here to read the rest:
Persuasive Speech: Genetic Engineering - Video

Gene sequencing program gives researchers new leads to improve cancer treatment

Newswise ANN ARBOR, Mich. It started with a 44-year-old woman with solitary fibrous tumor, a rare cancer seen in only a few hundred people each year.

By looking at the entire DNA from this one patients tumor, researchers have found a genetic anomaly that provides an important clue to improving how this cancer is diagnosed and treated.

Researchers at the University of Michigan Comprehensive Cancer Center sequenced the tumors genome through a new program called MI-ONCOSEQ, which is designed to identify genetic mutations in tumors that might be targeted with new therapies being tested in clinical trials.

The sequencing also allows researchers to find new mutations. In this case, an unusual occurrence of two genes NAB2 and STAT6 fusing together. This is the first time this gene fusion has been identified.

In most cases, mutations are identified because we see them happening again and again. Here, we had only one case of this. We knew NAB2-STAT6 was important because integrated sequencing ruled out all the known cancer genes. That allowed us to focus on what had been changed, says lead study author Dan R. Robinson, research fellow with the Michigan Center for Translational Pathology.

Once they found the aberration, the researchers looked at 51 other tumor samples from benign and cancerous solitary fibrous tumors, looking for the NAB2-STAT6 gene fusion. It showed up in every one of the samples. Results are published online in Nature Genetics.

Genetic sequencing is extremely important with rare tumors, says study co-author Scott Schuetze, M.D., associate professor of internal medicine at the U-M Medical School. Models of rare cancers to study in the laboratory are either not available or very limited. The sequencing helps us to learn more about the disease that we can use to develop better treatments or to help diagnose the cancer in others.

The NAB2-STAT6 fusion may prove to be a difficult target for therapies, but researchers believe they may be able to attack the growth signaling cycle that leads to this gene fusion.

Understanding the changes induced in the cell by the NAB2-STAT6 gene fusion will help us to select novel drugs to study in patients with advanced solitary fibrous tumors. Currently this is a disease for which there are no good drug therapies available and patients are in great need of better treatments, Schuetze says.

See more here:
Researchers Identify Genetic Mutation for Rare Cancer

The desire to seek thrills on the ski slope may be in your genes, according to new research.

The study, which involved about 500 skiers and snowboarders of intermediate to expert skill level, found that people who had a particular genetic marker were more likely to say they tried daredevil moves on the slopes than those without the marker.

For instance, people with the marker more often agreed with statements such as "I like to ski/ride fast" and "I like to go down runs that I have never been down before."

The findings held even after the researchers took into account factors that could affect thrill-seeking behavior, such as gender and skill level.

The marker is found within a gene involved in the creation of a brain receptor that binds to dopamine a chemical thought to play a role in reward-seeking behaviors. The marker may affect the number of dopamine receptors in the brain.

It's not clear how the marker could affect a person's behavior, said study researcher Cynthia Thomson, a Ph.D. student at the University of British Columbia's School of Kinesiology. But one possible explanation is that people with fewer dopamine receptors need a greater amount of stimulation (in the form of thrills) to reach the same level of arousal as people with more receptors, Thomson said.

However, the new study only found an association, so it doesn't prove that this genetic marker plays a role in thrill-seeking behavior, Thomson said. In addition, there are likely many genes that influence this type of behavior, which remain to be found.

Previous studies have investigated whether this genetic marker is linked with being an extrovert, or with seeking out new things in general. However, none have examined the connection between this marker and thrill-seeking in sports.

In addition, previous studies often question people about what they would do in hypothetical situations, but because the new study focused on skiers and snowboarders, it was able to inquire about people's actual behavior.

Thomson said sports may be a pro-social outlet for sensation-seeking, as opposed to more deviant outlets, such as substance abuse.

Read the original:
Skiers' Thrill-Seeking May Be Genetic

Proof of 2nd Hostboot
Proof against Genetics and walnut Match ID: 36030777

By: wargamesnerd

Link:
Proof of 2nd Hostboot - Video

Proof of 1st map hostboot
Proof against Genetics and walnut Match ID: 36030777

By: wargamesnerd

See the original post here:
Proof of 1st map hostboot - Video

Proof of 2nd map no-show
Proof against Genetics and walnut Match ID: 36030777

By: wargamesnerd

Excerpt from:
Proof of 2nd map no-show - Video

True Cannabliss #39; Girl Scout Cookies in the UK Emerald Triangle OG - Connoisseur Genetics
Well I don #39;t often get to go into seed breeders gardens so this is a treat for you! From the man who brought you the UK Casey Jones cutting, True Cannabliss takes us around his flower tent with three lovely strains - buds swelling like crazy as they are entering the thorough 21 day flush for that soft white ash. Triangle Emerald OG, Girl Scout Cookies, Grand Daddy Purple S1 by Connoisseur Genetics in the middle. Get yourself a 10% discount on all Connoisseur Genetics seeds at http://www.odysseed.nl - just shoot Frank an e-mail with the code "CONNOISSEURCURE" and he will apply that to your order when he processes it. Feel free to e-mail before hand. The two different freebies at the moment are also Connoisseur Genetics new strains...!!! Freebies - Grape Lemonade Fems (exclusive to Odysseed) Cheese Dawg Regulars! American orders recieve a 20% discount so why not have a taste of what the Brits have done with some classic UK American genetics.

By: CannabisCureTV

Go here to read the rest:
True Cannabliss' Girl Scout Cookies in the UK

Proof of 2nd map win
Proof against Genetics and walnut Match ID: 36030777

By: wargamesnerd

Read the rest here:
Proof of 2nd map win - Video

Systems Medicine at Georgetown University Medical Center
Howard J. Federoff, MD, PhD, executive vice president for health sciences at Georgetown University Medical Center, is acutely aware of the hurdles facing the introduction of a sweeping new vision for health care, systems medicine. Federoff sees this approach impacting, not only how patient care is delivered, but perhaps even more importantly, how GUMC teaches, conducts research and engages with the community. As a concept, systems medicine is at once complex and straightforward. Federoff describes it as an approach that will allow health care providers to understand the interplay between genetics and the environment in such a way that they will be able to predict who is at greatest risk for disease, rather than simply reacting to symptoms.

By: GeorgetownToday

Continue reading here:
Systems Medicine at Georgetown University Medical Center - Video

CGR Undertow - RIDING STABLES: RIVALS IN THE SADDLE 3D review for Nintendo 3DS
Riding Stables: Rivals In The Saddle 3D video review. Classic Game Room presents a CGR Undertow video review of Riding Stables: Rivals In The Saddle 3D, a downloadable game from TREVA Entertainment on the eShop for the Nintendo 3DS. Riding Stables is a fun pet simulator for kids. There are 30 different tasks to do, from grooming your horses to feeding them and playing rhythm games. Because horses only win ribbons if they can master Elite Beat Agents. There are 26 different breeds to choose from, and you can even adjust their genetics, if you #39;re into that kind of thing. This video review features video gameplay footage of Riding Stables: Rivals In The Saddle 3D for the Nintendo 3DS and audio commentary from Classic Game Room #39;s Derek. Check out more reviews from Classic Game Room at: http://www.YouTube.com and http://www.YouTube.com For the latest trailers, visit http://www.YouTube.com And connect with us at: http://www.ClassicGameRoom.com http http://www.gplus.to http://www.Twitter.com http://www.Twitter.com

By: CGRundertow

Original post:
CGR Undertow - RIDING STABLES: RIVALS IN THE SADDLE 3D review for Nintendo 3DS - Video

Never get between a Woman and her MONEY
My Daughter Layla (1 1/2) fighting her 16 year uncle over a $5 bill. and she is biting him... Just goes to show that Woman are drawn to money at a young age, It is in there genetics....

By: Stephen Booth

More:
Never get between a Woman and her MONEY - Video

The Life Sciences Facility - Time Lapse Video
The new facility is an exciting expansion for the teaching and research capabilities of the College of Agriculture, Forestry and Life Sciences at Clemson University. Here, some of the country #39;s brightest minds will come together to share the latest technology and the most up-to-date laboratory space. The 100000-square-foot facility is targeted to achieve LEED gold status. Researchers housed in the facility represent microbiology, biochemistry, food safety and genetics mdash; the basics of human existence. The new Life Sciences facility encourages collaboration, offers state-of-the-art technology and provides the tools needed for this generation #39;s greatest minds to excel.

By: clemsonpsa

Read more here:
The Life Sciences Facility - Time Lapse Video - Video

2012 Nikon Small World in Motion - Honorable Mention
Beating heart of a Danio rerio (zebrafish) (20x) Michael Weber, Max Planck Institute of Molecular Cell Biology and Genetics For more information on this winning movie, go to http://www.nikonsmallworld.com

By: NikonMicroscopes

Read the original:
2012 Nikon Small World in Motion - Honorable Mention - Video